Illiteracy and Vulnerability to Alzheimer's Disease: Evaluation of Amyloid Pathology by PET Imaging (AVILL)

January 12, 2021 updated by: Assistance Publique - Hôpitaux de Paris
The goal of this study is to improve the diagnosis of Alzheimer's disease (AD) at two different stages (MCI and dementia) in illiterate subjects, using FDG- fluorodeoxyglucose - and florbetapir F 18 -PET imaging. This study will compare amyloid load and cerebral metabolism dysfunction in literate versus illiterate MCI and AD patients.

Study Overview

Detailed Description

Illiterate, with a higher rate in the elder and in multi-cultural population reaching, then, 20%. Most of these patients are not usually included in research studies.

Thus, AVILL would specifically focus on lower educated and illiterate patients and on use of PET imaging for early diagnosis. This study would take advantage of the collaboration with the recently launched Memento cohort.

RATIONALE:

  1. The diagnosis of AD at the early stages of the disease appears to be crucial. MCI is now considered as the 1st clinical stage of the disease, after a long pre-clinical period.
  2. Cognitive reserve modulates the relationship between cerebral lesions and their clinical manifestations by limiting the negative impact of cerebral lesion on cognition. Education is a commonly-used proxy of cognitive reserve. Education interacts with AD pathology such that a greater pathological burden is required to show an effect on cognition among subjects with more education. Lower education and illiteracy are thus considered as risk factor of developing AD
  3. Diagnosing MCI and AD in lower educated and illiterate patients is a real challenge because of:

    1. -difficulties in cognitive evaluation which mostly relies on educational background and reading abilities,
    2. -poor adaptation of neuropsychological tests,
    3. -lack of clinical and imaging data concerning these patients, who are often excluded from studies, and poor knowledge of the evolution of the disease from the earlier signs (MCI) to dementia.
  4. Quantification of amyloid deposit by PET imaging could therefore be useful for the diagnosis of AD in illiterate patients.

GENERAL OBJECTIVES:

  • non educated patient amyloid load could differ from educated patient amyloid load at the same stage of cognitive impairment
  • PET amyloid imaging using florbetapir F 18 could detect non educated patients with AD risk at early stage and could help clinical evaluation which is particularly difficult in this population.
  • uptake level of florbetapir F 18 could be different in MCI and AD non educated patients compared to educated patients which are the basis of the objectives.

Study Type

Interventional

Enrollment (Actual)

45

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bobigny, France, 93000
        • Hospital Avicenne-Neurology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. For all patients enrolled in the study:

    • Aged 18 years and above
    • Visual and auditory acuity adequate for neuropsychological testing
    • Having signed an informed consent
    • Being affiliated to health insurance
  2. For MCI patients:

    For this group, the criteria are the same as those of Memento but with specially designed neuropsychological tests for illiterate/low educated patients.

    • Performing worse than one standard deviation to the mean (compared to age and educational norms) in one or more cognitive domains (neuropsychological tests battery exploring memory, language, praxis, vision, executive functions); this deviation is required to be documented by tests performed less than 6 months age
    • Clinical dementia Rating scale < or = 0.5
  3. For AD patients

    • Fulfilling DSM IV criteria of AD
    • Clinical Dementia Rating scale > 0.5 Patients are defined as "illiterate" having 5 or less years of schooling, and "literate" when having more than 5 years

Exclusion Criteria:

  • Being under guardianship
  • Residence in skilling nursing facility
  • Pregnant or breast feeding women
  • Alzheimer's disease caused by gene mutations
  • Brain MRI exclusion criteria (pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin, or body) or refusing MRI
  • Neurological disease such as: treated epilepsy, treated Parkinson's disease, Huntington disease, brain tumour, subdural haematoma, progressive supranuclear palsy, history of head trauma followed by persistent neurological deficits, history of stroke
  • Schizophrenia or other psychiatric history (DSM-IV criteria)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Positon Emission Tomographic (PET)-scan
2 PET-scan: Fluorodeoxyglucose-PET and florbetapir F 18-PET
Fluorodeoxyglucose-PET performed within 2 months
florbetapir F 18-PET performed within 2 months

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Comparison of the amount of amyloid deposits using florbetapir-18 Fluor-PET between illiterate and literate MCI patients
Time Frame: Within 2 months after inclusion
Comparison between the 2 groups (educated and non -educated) of florbetapir-18 Fluor Standardized Uptake Values (SUV) ratios (max and mean of SUVr) in MCI patients
Within 2 months after inclusion

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Comparison of the amount of amyloid deposits using florbetapir-18 Fluor-PET between illiterate and literate AD patients,
Time Frame: Within 2 months after inclusion
Comparison of florbetapir-18 Fluor SUV (Standardized Uptake Values) ratios (max and mean of SUVr) in the different groups as defined above
Within 2 months after inclusion
Comparison of the amyloid deposit location between the 2 groups (literate and illiterate)
Time Frame: Within 2 months after inclusion
Group comparison of qualitative topography of amyloid burden
Within 2 months after inclusion
correlation between amyloid load and metabolism dysfunction using Fluorodeoxyglucose (FDG)-PET in each groups
Time Frame: Within 2 months after inclusion
Group comparison of topography of amyloid deposit and FDG metabolism
Within 2 months after inclusion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Catherine Belin, Dr, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS (hospial Avicenne)
  • Study Director: AMEL OUSLIMANI, PM, Assistance Publique - Hôpitaux de Paris, DRCD

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 12, 2015

Primary Completion (Actual)

May 6, 2019

Study Completion (Actual)

May 6, 2020

Study Registration Dates

First Submitted

May 4, 2015

First Submitted That Met QC Criteria

July 9, 2015

First Posted (Estimate)

July 10, 2015

Study Record Updates

Last Update Posted (Actual)

January 13, 2021

Last Update Submitted That Met QC Criteria

January 12, 2021

Last Verified

December 1, 2020

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Alzheimer Disease

Clinical Trials on Fluorodeoxyglucose-PET

3
Subscribe